We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Outperforms Broader Market: What You Need to Know
Read MoreHide Full Article
In the latest trading session, McKesson (MCK - Free Report) closed at $884.28, marking a +1.37% move from the previous day. This change outpaced the S&P 500's 0.11% gain on the day. At the same time, the Dow lost 0.13%, and the tech-heavy Nasdaq gained 0.18%.
Shares of the prescription drug distributor have depreciated by 10.87% over the course of the past month, underperforming the Medical sector's loss of 6.43%, and the S&P 500's loss of 4.28%.
Investors will be eagerly watching for the performance of McKesson in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 7, 2026. The company's upcoming EPS is projected at $11.5, signifying a 13.64% increase compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $101.91 billion, reflecting a 12.21% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $38.95 per share and a revenue of $408.94 billion, representing changes of +17.85% and +13.89%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for McKesson. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 0.1% higher. McKesson is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note McKesson's current valuation metrics, including its Forward P/E ratio of 19.8. This valuation marks a premium compared to its industry average Forward P/E of 15.47.
It's also important to note that MCK currently trades at a PEG ratio of 1.24. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Medical - Dental Supplies industry was having an average PEG ratio of 1.76.
The Medical - Dental Supplies industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 58, positioning it in the top 24% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
McKesson (MCK) Outperforms Broader Market: What You Need to Know
In the latest trading session, McKesson (MCK - Free Report) closed at $884.28, marking a +1.37% move from the previous day. This change outpaced the S&P 500's 0.11% gain on the day. At the same time, the Dow lost 0.13%, and the tech-heavy Nasdaq gained 0.18%.
Shares of the prescription drug distributor have depreciated by 10.87% over the course of the past month, underperforming the Medical sector's loss of 6.43%, and the S&P 500's loss of 4.28%.
Investors will be eagerly watching for the performance of McKesson in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 7, 2026. The company's upcoming EPS is projected at $11.5, signifying a 13.64% increase compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $101.91 billion, reflecting a 12.21% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $38.95 per share and a revenue of $408.94 billion, representing changes of +17.85% and +13.89%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for McKesson. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 0.1% higher. McKesson is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note McKesson's current valuation metrics, including its Forward P/E ratio of 19.8. This valuation marks a premium compared to its industry average Forward P/E of 15.47.
It's also important to note that MCK currently trades at a PEG ratio of 1.24. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Medical - Dental Supplies industry was having an average PEG ratio of 1.76.
The Medical - Dental Supplies industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 58, positioning it in the top 24% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.